Cellectis (CLLS) Cash from Discontinued Operations (2022 - 2023)

Cellectis (CLLS) recorded quarterly Cash from Discontinued Operations of 1000.0 in Q4 2023, up 200.0% quarter-over-quarter from 1000.0 in Q3 2023, and up 100.0% on a YoY basis from 499.99 in Q4 2022.

Cellectis (CLLS) Cash from Discontinued Operations (2022 - 2023) Analysis & Trends

Cellectis' Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 1000.0 for Q4 2023.

  • In Q4 2023, Cash from Discontinued Operations rose 100.0% year-over-year to 1000.0; the TTM figure through Dec 2023 stood at 3644000.0 (up 80.41% YoY), while the FY2023 annual figure was 3644000.0, up 80.41% from the prior year.
  • Cash from Discontinued Operations was 1000.0 for Q4 2023 at Cellectis, up from 1000.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 17285000.0 in Q1 2022 to a low of 25632000.0 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -59.14 Mn
10 Cellectis 17.40 Bn 17.21 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 1,000.00
Dec 31, 2023 1,000.00
Sep 30, 2023 -1,000.00
Sep 30, 2023 -1,000.00
Jun 30, 2023 -5.70 Mn
Jun 30, 2023 -5.70 Mn
Mar 31, 2023 2.05 Mn
Mar 31, 2023 2.05 Mn
Dec 31, 2022 -25.63 Mn
Dec 31, 2022 -25.63 Mn
Sep 30, 2022 -4.29 Mn
Sep 30, 2022 -4.29 Mn
Jun 30, 2022 -5.97 Mn
Jun 30, 2022 -5.97 Mn
Mar 31, 2022 17.29 Mn
Mar 31, 2022 17.29 Mn